160,156 Shares in Certara, Inc. (NASDAQ:CERT) Bought by Advantage Alpha Capital Partners LP

Advantage Alpha Capital Partners LP acquired a new position in shares of Certara, Inc. (NASDAQ:CERT) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 160,156 shares of the company’s stock, valued at approximately $1,875,000.

Other large investors have also recently bought and sold shares of the company. Blue Trust Inc. acquired a new position in shares of Certara in the 2nd quarter valued at approximately $26,000. Innealta Capital LLC acquired a new position in Certara during the second quarter valued at approximately $36,000. KBC Group NV lifted its stake in Certara by 48.2% during the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after purchasing an additional 1,584 shares during the last quarter. Intech Investment Management LLC bought a new stake in Certara during the second quarter worth $152,000. Finally, Algert Global LLC acquired a new stake in shares of Certara in the 2nd quarter valued at $156,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the sale, the insider now owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. This represents a 33.94 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Patrick F. Smith sold 5,409 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. The trade was a 9.75 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.39% of the company’s stock.

Certara Price Performance

Certara stock opened at $11.05 on Tuesday. The stock has a 50-day moving average price of $10.80 and a two-hundred day moving average price of $13.13. Certara, Inc. has a 12 month low of $9.41 and a 12 month high of $19.87. The company has a market capitalization of $1.78 billion, a PE ratio of -55.25, a P/E/G ratio of 5.24 and a beta of 1.51. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business had revenue of $94.80 million during the quarter, compared to analyst estimates of $95.51 million. During the same quarter last year, the business earned $0.06 EPS. The firm’s quarterly revenue was up 10.7% on a year-over-year basis. Analysts expect that Certara, Inc. will post 0.28 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on CERT shares. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a report on Friday, September 27th. Barclays lowered their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, November 7th. Finally, Robert W. Baird reduced their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 5th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $15.92.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.